Inogen, Inc. (NASDAQ:INGN) Short Interest Update

Inogen, Inc. (NASDAQ:INGN) saw a significant increase in short interest during the month of January. As of January 31st, there was short interest totalling 798,600 shares, an increase of 8.8% from the January 15th total of 734,000 shares. Based on an average daily trading volume, of 224,800 shares, the short-interest ratio is currently 3.6 days.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on INGN. StockNews.com raised Inogen from a “hold” rating to a “buy” rating in a research report on Monday, February 10th. Needham & Company LLC reissued a “hold” rating on shares of Inogen in a research report on Thursday, January 30th.

Inogen Stock Down 0.2 %

INGN stock traded down $0.02 during midday trading on Friday, hitting $10.64. The company’s stock had a trading volume of 340,965 shares, compared to its average volume of 262,340. The stock’s 50-day moving average price is $10.07 and its 200 day moving average price is $10.24. Inogen has a 1 year low of $5.82 and a 1 year high of $13.33. The stock has a market cap of $253.44 million, a price-to-earnings ratio of -4.73 and a beta of 1.02.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. Connor Clark & Lunn Investment Management Ltd. boosted its position in Inogen by 312.5% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 174,625 shares of the medical technology company’s stock worth $1,694,000 after purchasing an additional 132,287 shares during the last quarter. JPMorgan Chase & Co. lifted its position in shares of Inogen by 2.7% during the 3rd quarter. JPMorgan Chase & Co. now owns 896,106 shares of the medical technology company’s stock valued at $8,692,000 after buying an additional 23,891 shares during the last quarter. Barclays PLC lifted its position in shares of Inogen by 72.9% during the 3rd quarter. Barclays PLC now owns 55,508 shares of the medical technology company’s stock valued at $539,000 after buying an additional 23,398 shares during the last quarter. Geode Capital Management LLC lifted its position in shares of Inogen by 1.1% during the 3rd quarter. Geode Capital Management LLC now owns 554,191 shares of the medical technology company’s stock valued at $5,377,000 after buying an additional 5,921 shares during the last quarter. Finally, Franklin Resources Inc. purchased a new position in shares of Inogen during the 3rd quarter valued at $139,000. Hedge funds and other institutional investors own 89.94% of the company’s stock.

Inogen Company Profile

Inogen, Inc, a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.